Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections - Seite 2

Nachrichtenquelle: globenewswire
01.03.2021, 13:30  |  384   |   |   

R-107, on the other hand, is a breakthrough compound designed to overcome the limitations of nitric oxide inhalation therapy.

  • R-107 – A Potentially Superior Route of Administration Transforms Nitric Oxide into a Practical Therapy
    Unlike nitric oxide gas, which must be administered as an inhalation therapy, R-107 is a liquid that may be readily administered orally in a capsule, or nasally though use of a nasal spray, or by a single intramuscular or subcutaneous injection. Due to its ease of administration, R-107 is expected to allow treatment without the need for special delivery equipment or trained respiratory therapists. In this manner, R-107 may overcome the challenges inherent in the administration of nitric oxide gas, and transform nitric oxide therapy into a potentially best-of-care treatment for COVID-19 infection, and potentially other viral infections as well.
  • R-107 – Designed to Act Throughout the Body – Not Only in the Lungs
    When inhaled, nitric oxide gas is absorbed into the lung tissues, where it has a half-life of only a few seconds. Accordingly, it is believed that inhaled nitric oxide may eliminate virus in the lungs, but does not survive long enough within the circulation to reach distant organs and eliminate their viral infection. In contrast, following administration of R-107 by either the oral, or nasal or injectable route, R-107 enters the bloodstream, where it is stable and can slowly release nitric oxide systemically over 24 hours. R-107’s systemic release of nitric oxide would thus potentially allow elimination of virus in all organs and tissues, not only in the lungs.

    In addition to its apparent advantages in systemic administration and simplicity of administration, R-107 does not lose its potency after prolonged periods of clinical use. In contrast, other nitric oxide donors in liquid form, such as nitroglycerin and amyl nitrate, rapidly induce tolerance and lose their biological activity after more than a single dose. Accordingly, R-107 is poised to become a more effective, less expensive, and more easily administered form of nitric oxide that could potentially transform this agent into a frontline therapy against COVID-19 and other viral infections.

“R-107 will play an important role in the fight against COVID-19, and vaccine-resistant variants of the COVID-19 virus. We intend to become a leader in the race to find a treatment for COVID-19, and we are well positioned to achieve this goal,” stated Robert Farrell, President and CEO of Claritas. “However, our goal is more ambitious than that: we intend to develop R-107 as a broad-spectrum antiviral drug for the treatment of, and possible prevention of, future viral outbreaks. We are working closely with the Salzman Group to develop R-107 to treat, and possibly prevent, COVID-19 infection, as well as influenza and common colds caused by adenovirus, coronavirus and influenza virus.”

Seite 2 von 4
Claritas Pharmaceuticals Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections - Seite 2 SAN FRANCISCO and TORONTO, March 01, 2021 (GLOBE NEWSWIRE) - Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.), (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that the Company will …


Nachrichten des Autors